MedTrace Logo

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

NCT03066206 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2026-02-20

No results posted yet for this study

Summary

This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..

Conditions

  • EGFR Exon 20 Mutation
  • ERBB2 Gene Mutation
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

DRUG

Poziotinib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Spectrum Pharmaceuticals, Inc

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Yasir Y Elamin · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2026-02-16
Completion
2026-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066206 on ClinicalTrials.gov